The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...
First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after ...
Maryland Gov. Wes Moore said he plans to introduce a balanced budget that prioritizes education and safety in the final ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
BostonGene, the developer of an AI foundation model for tumor and immune biology, has entered a strategic collaboration with ...
BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company ...
BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...
Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation ...
TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...
US biotech BostonGene has struck a research collaboration with British pharma AstraZeneca (LSE: AZN) to explore the use of ...
Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...
The data presented covered everything from its mainstay acalabrutinib, sold as Calquence, to the eye-catching AZD0120, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback